Home/ Stocks/ ALGS

Aligos Therapeutics, Inc. Common Stock

ALGS XNAS

$5.59 +0.08 (+1.45%) ▲ 15-min delayed

Open

$5.50

High

$6.15

Low

$5.25

Volume

335.8K

Market Cap

$34.10M

About Aligos Therapeutics, Inc. Common Stock

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 82 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.83M	$-23,040,000	$-2.21
FY 2025	$2.19M	$-24,193,000	$-2.45
Q3 2025	$741.0K	$-31,537,000	$-3.04
Q2 2025	$965.0K	$-15,863,000	$-1.53

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for ALGS yet. Check out our latest market news or earnings calendar.

Get ALGS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aligos Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.